We have developed and optimised a novel, highly sensitive, electrochemical molecular assay, for the detection of Chlamydia trachomatis. Performance of this assay has been evaluated in terms of speed to result, analytical sensitivity (limit of detection) and specificity, to assess the value of employing this methodology within a clinical setting.
In addition, we have evaluated the use of a range of different electrochemical labels in a multiplex assay for simultaneous detection of Chlamydia trachomatis and Neisseria gonorrhoeae together with an internal control DNA sequence, to investigate the possibility of utilising the electrochemical detection methodology to identify multiple targets within a single sample.
The objective of this work was to validate the electrochemical detection technology for use in a point-of-care environment, and to provide a robust panel of tests that can be integrated onto the Atlas Genetics Velox™ rapid point-of-care platform, which is currently under development.
Access the full PDF publication, sign into "the Hub" now - click here